Abstract | BACKGROUND AND PURPOSE: METHODS: RESULTS: sGPVI was elevated in stroke compared with controls (P=0.0168). ORs were higher in Quartile 4 for stroke cases (P=0.0121), and sGPVI was significantly elevated in stroke associated with large artery disease across Quartiles 2 to 4 and small artery disease in Quartile 4. sGPVI decreased 3 to 6 months after antiplatelet treatment, consistent with elevated sGPVI due to platelet activation during the thrombotic event. sGPVI correlated with P-selectin (P=0.0007) and was higher in individuals with the GPVIa haplotype (P=0.024). CONCLUSIONS:
|
Authors | Mohammad Al-Tamimi, Elizabeth E Gardiner, Jim Y Thom, Yang Shen, Matthew N Cooper, Graeme J Hankey, Michael C Berndt, Ross I Baker, Robert K Andrews |
Journal | Stroke
(Stroke)
Vol. 42
Issue 2
Pg. 498-500
(Feb 2011)
ISSN: 1524-4628 [Electronic] United States |
PMID | 21193745
(Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Biomarkers
- Platelet Membrane Glycoproteins
- platelet membrane glycoprotein VI
|
Topics |
- Acute Disease
- Aged
- Atherosclerosis
(blood, complications, pathology)
- Biomarkers
(blood)
- Brain Ischemia
(blood, etiology, pathology)
- Cohort Studies
- Female
- Humans
- Male
- Platelet Membrane Glycoproteins
(metabolism)
- Solubility
- Stroke
(blood, etiology, pathology)
|